Regadenoson: a focused update.
Gopal Ghimire1, Fadi G Hage, Jaekyeong Heo
1Division of Cardiovascular Diseases, University of Alabama at Birmingham, 318 LHRH, 1900, University Blvd, Birmingham, AL 35294, USA.
Summary
Regadenoson is a widely used vasodilator for myocardial perfusion imaging (MPI). Recent studies update its safety in specific patient groups and explore its use in hybrid protocols, offering prognostic insights.
Area of Science:
- Cardiology
- Nuclear Medicine
- Pharmacology
Background:
- Regadenoson, approved in 2008, is the leading vasodilator for myocardial perfusion imaging (MPI) in the US.
- Prior reviews covered pre-clinical and clinical data; this update focuses on recent findings.
Purpose of the Study:
- To provide a focused update on regadenoson use for MPI.
- To summarize emerging data on safety in special patient populations and novel applications.
Main Methods:
- Review of recent clinical data and studies.
- Focus on safety in patients with chronic kidney disease, airway disease (asthma, COPD), and liver disease.
- Evaluation of regadenoson in hybrid MPI protocols with exercise.
Main Results:
- Regadenoson demonstrates established safety and efficacy in myocardial perfusion imaging.
- Emerging data support its use in patients with comorbidities like kidney, airway, and liver disease.
- Hybrid protocols show promise for improved patient tolerance and image quality, with available prognostic data.
Conclusions:
- Regadenoson remains a cornerstone vasodilator for MPI.
- Recent data expand its application profile and confirm its prognostic value.
- Continued research in hybrid protocols and special populations will further refine its clinical utility.
Related Concept Videos
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:28Imaging Studies for Cardiovascular System V: CT
Cardiac computed tomography (CT) scanning is an advanced cardiac imaging technique that utilizes CT technology, with or without intravenous (IV) contrast, to produce accurate cross-sectional virtual slices of specific areas of the heart, coronary circulation, and major blood vessels such as the aorta, pulmonary veins, and arteries. The computer processes these slices to generate three-dimensional images. Multidetector CT (MDCT) is a rapid form of CT scanning that captures multiple slices...
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:19Imaging Studies VII: Vascular Imaging
DefinitionRenal angiography, also known as renal arteriography, is an imaging technique used to obtain a comprehensive view of blood flow and the vascular structure of blood vessels in the kidneys and surrounding areas.PurposeRenal angiography detects blood vessel abnormalities in the kidneys, such as aneurysms, stenosis, thrombosis, vascular tumors, and renal artery stenosis. It evaluates kidney function and guides interventional treatments like angioplasty or stent placement.Pre-Procedure...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...